Safety and efficacy of ciprofol for sedation in intensive care unit patients with severe neurological disorder

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065731

Enrollment

Unknown

Registered

2022-11-14

Start date

2023-11-20

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe neurological disorder

Interventions

group C :ciprofol

group P :propofol

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, no gender limit; 2. Hypertensive cerebral hemorrhage, intracranial aneurysm, massive cerebral infarction and other severe neurological treatment (GCS>8 points); 3. Endotracheal intubation was not removed after surgery, and mechanical assisted ventilation was continued after admission to ICU; 4. No obvious damage to liver and kidney function, no degree II or above atrioventricular block indicated by electrocardiogram, sinus bradycardia, no history of taking psychotropic drugs; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Endangered patients with unstable shock circulation before admission; 2. Death or automatic discharge after admission to ICU24h; 3. Pregnant patients and patients with previous mental diseases.

Design outcomes

Primary

Measure	Time frame
Mean arterial pressure;Heart rate;Use of vasoactive drugs;Use of other sedative and analgesic drugs;Dosage of ciprofol;Glasgow Coma Index Scale (GCS) Score;Cerebral oxygen saturation;Event-related potential;	—

Countries

China

Contacts

Public ContactGao Jianling

Dushu Lake Hospital Affiliated to Soohow University

571177307@qq.com+86 13771815313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026